Development of aggregation inhibitors for amyloid-β peptides and their evaluation by quartz-crystal microbalance

Chemical Biology and Drug Design

Volumn 69, Issue 5, 2007, Pages 356-361

  Okuno, Hiroaki ^a   Mori, Kanae ^a   Okada, Tomoko ^b   Yokoyama, Yuusaku ^a   Suzuki, Hideharu ^a  

^a TOHO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Aggregation disruption; Aggregation inhibitor; Alzheimer's disease; Amyloid beta; Quartz crystal microbalance; Reduced cytotoxicity

Indexed keywords

AMINO ACID DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PROTEIN INHIBITOR; SILICON DIOXIDE;

ANALYTIC METHOD; ARTICLE; BIOASSAY; CONTROLLED STUDY; CRYSTAL; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; ELECTRICITY; ELECTRODE; HUMAN; HUMAN CELL; HYDROPHILICITY; INHIBITION KINETICS; MOLECULAR RECOGNITION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUARTZ CRYSTAL MICROBALANCE;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; EVALUATION STUDIES; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; QUARTZ; TUMOR CELLS, CULTURED;

EID: 34249332787     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00509.x     Document Type: Article

References (22)

1. Uversky V.N., Fink A.L. (2004) Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 1698 : 131 153.
2. Aguzzi A., Polymenidou M. (2004) Mammalian prion biology: One century of evolving concepts. Cell 116 : 313 327.
3. Aguzzi A., Haass C. (2003) Games played by Rogue proteins in prion disorders and Alzheimer's Disease. Science 302 : 814 819.
4. Selkoe D.J. (2003) Folding proteins in fatal ways. Nature 426 : 900 904
5. Hardy J.A., Higgins G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256 : 184 185.
6. Zarandi M., Soos K., Fulop L., Bozso Z., Datki Z., Toth G.K., Penke B. (2007) Synthesis of Aβ (1-42) and its derivatives with improved efficiency. J Peptide Sci 13 : 94 99.
7. Yoshiike Y., Tanemura K., Murayama O., Akagi T., Murayama M., Sato S., Sun X., Tanaka N., Takashima A. (2001) New insights on how metals disrupt amyloid β-aggregation and their effects on amyloid-β cytotoxicity. J Biol Chem 276 : 32293 32299.
8. Okuno H., Mori K., Tomofumi J., Inoue H., Chiba S. (2006) Convenient Method for Monitoring Aβ Aggregation by Quartz-Crystal Microbalance. Chem Biol Drug Des 68 : 273 275.
9. Inaba S., Okada T., Konakahara T., Kodaka M. (2005) Specific binding of amyloidb-protein to IMR-32 neuroblastoma cell membrane. J Peptide Res 65 : 485 490.
10. Boland K., Behrens M., Choi D., Manias K., Perlmutter D.H. 1996) The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-β peptide but not aggregated, cytotoxic amyloid-β peptide. J Biol Chem 271 : 18032 18044.
11. Sinha S., Lieberburg I. (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96 : 11049 11053.
12. Suh Y.-H., Checler F. (2002) Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54 : 469 525.
13. Watanabe K., Nakamura K., Akikusa S., Konakahara T., Okada T., Kodaka M., Okuno H. (2002) Inhibitors of Fibril Formation and Cytotoxicity of β-Amyloid Composed of KLVFF Recognition Element and Flexible Hydrophilic Disrupting Element. Biochem Biophys Res Commun 290 : 121 124.
14. Akikusa S., Nakamura K., Watanabe K., Horikawa E., Konakahara T., Kodaka M. Okuno H. (2003) Practical assay and molecular mechanism of aggregation inhibitor of β-amyloid. J Peptide Res 61 : 1 6.
15. Watanabe K., Segawa T., Nakamura K., Kodaka M., Konakahara T., Okuno H. (2001) Identification of the molecular-interaction site of amyloid β protein by fluorescence assay. J Peptide Res 58 : 342 346.
16. Okuno H., Mori K., Okada T. Synthesis of amyloid aggregation inhibitors and its evaluation by QCM Alzheimer's Disease: New Advances, Collection of Selected Articles of Papers Presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (Madrid, Spain, July 15-20, 2006), 451-454 (2007), Editors: Khalid Iqbal, Bengt Winblad, Jesus Avila, by MEDIMOND S.r.l., Italy.
17. Koskinen A.M.P., Valo T., Vihavainen S., Hakala J.M.L. (1995) Synthesis of α-helix substituted analogs of calcitonin gene-related peptide. Bioorg Med Chem Lett 5 : 573 578.
18. Spetzler J.C., Hoeg-Jensen T. (2002) Masked side-chain aldehyde amino acids for solid-phase synthesis and ligation. Tetrahedron Lett 43 : 2303 2306.
19. Carmichael J., Degraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. (1987) Evaluation of a tetrazolium-basedsemiautomated colorimetric assay:assessment of chemosensitivity testing. Cancer Res 47 : 936 942.
20. Ebara Y., Okahata Y. (1933) In situ surface-detecting technique by using a quartz-crystal microbalance. Interaction behaviors of proteins onto a monolayer at the air-water interface. Langmuir 9 : 574 576.
21. Sato T., Serizawa T., Okahata Y. (1994) Recognition of monosialoganglioside (GM3) reconstituted in sphingomyerin and glucosylceramide membranes against wheat germ agglutinin: quantitative analysis by a quartz crystal microbalance. Biochem Biophys Res Commun 204 : 551 556.
22. Sato T., Serizawa T., Okahata Y. (1996) Binding of influenza A virus to monosialoganglioside (GM3) reconstituted in glucosylceramide and sphingomyelin membranes. Biochim Biophys Acta 1285 : 14 20.